14 Mar 2007 : Column 422W—continued
Cancer: Medical Treatments
Mr. Leech:
To ask the Secretary of State for Health what estimate she has made of the financial impact on the NHS of positive National Institute for Health and Clinical Excellence (NICE) appraisals for medicines for (a) lung cancer, (b) breast cancer, (c) prostate cancer, (d) bowel cancer and (e) less common cancers in each year since NICE was established. [123646]
Caroline Flint:
Each technology appraisal published by the National Institute for Health and Clinical Excellence (NICE) contains an estimate of the cost to the national health service of its implementation. The table sets out NICE’s published cost impact estimates for appraisals in the relevant topic areas, up to February 2007.
| Technology appraisal | Date of issue | NICE estimates of full-year costs—England (£ million) |
|
Breast cancer
| | |
|
Taxanes for breast cancer
|
June 2000
|
16
|
|
Taxanes for breast cancer—review
|
September 2001
|
(1)0
|
|
Trastuzumab for breast cancer
|
March 2002
|
17
|
|
Vinorelbine for breast cancer
|
December 2002
|
6.5
|
|
Capecitabine for locally advanced breast cancer
|
May 2003
|
-1.2
|
|
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
|
August 2006
|
99.8
|
|
Docetaxel for early breast cancer
|
September 2006
|
8.8
|
|
Paclitaxel for early breast cancer
|
September 2006
|
(1)0
|
|
Hormonal treatments for early breast cancer
|
November 2006
|
17.4
|
|
Gemcitabine for metastatic breast cancer
|
January 2007
|
0.08
|
| | | |
|
Prostate cancer
| | |
|
Docetaxel for hormone refractory prostate cancer
|
June 2006
|
19.9
|
| | | |
|
Bowel cancer
| | |
|
Laparoscopic surgery for colorectal cancer
|
January 2001
|
(1)0
|
|
Capecitabine and tegafur with uracil for metastatic colorectal cancer
|
May 2003
|
-16
|
|
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
|
April 2006
|
10.3
|
|
Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer—review
|
August 2005
|
56
|
|
Laparoscopic surgery for colorectal cancer
|
August 2006
|
0.8
|
|
Bevacizumab and cetuximab for metastatic colorectal cancer
|
January 2007
|
(1)0
|
| | | |
|
Less common cancers
| | |
|
Taxanes for ovarian cancer
|
May 2000
|
7
|
|
Liquid Based Cytology for cervical screening
|
June 2000
|
(1)0
|
|
Temozolomide for brain cancer
|
April 2001
|
1
|
|
Gemcitabine for pancreatic cancer
|
May 2001
|
1.9
|
|
Topetecan for advanced ovarian cancer
|
August 2001
|
7
|
|
Fludarabine for B-cell chronic lymphocytic leukaemia
|
September 2001
|
(1)0
|
|
Rituximab for follicular non-Hodgkin’s lymphoma
|
March 2002
|
(1)0
|
|
PLDH (Caelyx) for ovarian cancer
|
July 2002
|
3.1
|
|
Imatinib for chronic myeloid leukaemia.
|
October 2002
|
15.8
|
|
Paclitaxel for ovarian cancer
|
January 2003
|
(1)0
|
|
Rituximab for aggressive non-Hodgkin’s lymphoma
|
September 2003
|
13.15
|
|
Liquid-based cytology for cervical screening—review
|
October 2003
|
10.1-10.3
|
|
Imatanib for chronic myeloid leukaemia
|
October 2003
|
5
|
|
Imatinib for gastro-intestinal stromal tumours (GIST)
|
October 2004
|
4.7
|
14 Mar 2007 : Column 423W
14 Mar 2007 : Column 424W
|
Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for ovarian cancer (advanced)—review
|
May 2005
|
2.25
|
|
Rituximab for follicular lymphoma
|
September 2006
|
3.4
|
|
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
|
February 2007
|
(1)0
|
(1) Not considered to have significant cost implications.
|
Cancer: Northern Region
David Maclean:
To ask the Secretary of State for Health what funding (a) Cumbria primary care trust and (b) each other primary care trust in the north of England has been allocated for cancer treatment in 2006-07. [123257]
Ms Rosie Winterton:
We do not hold information centrally on levels of local funding allocations to primary care trusts (PCTs) for cancer treatment. However around £3.4 billion was spent on cancer services in 2003-04 and this increased by 12 per cent. each year to around £3.8 billion in 2004-05, and £4.3 billion in 2005-06.
National health service funding is allocated to PCTs to meet the health needs of their local population, who in partnership with strategic health authorities and other local stakeholders, determine how best to use their funds to meet national and local priorities for cancer services.
The following table shows the allocations to PCTs in the north of England for 2006-07.
| Primary care trust | Revenue allocation 2006-07 (£ million) |
|
Cumbria
|
632.5
|
|
North Lancashire
|
418.8
|
|
Blackpool
|
213.8
|
|
Central Lancashire
|
556.4
|
|
East Lancashire
|
506.2
|
|
Blackburn with Darwen Teaching
|
207.7
|
|
Sefton
|
389.7
|
|
Wirral
|
459.5
|
|
Liverpool
|
733.2
|
|
Knowsley
|
243.4
|
|
Halton and St. Helens
|
434.7
|
|
Warrington
|
237.1
|
|
Western Cheshire
|
303.8
|
|
Central and Eastern Cheshire
|
522.8
|
|
Ashton, Leigh and Wigan
|
410.7
|
|
Bolton
|
355.3
|
|
Bury
|
226.7
|
|
Heywood, Middleton and Rochdale
|
288.7
|
|
Salford Teaching
|
346.8
|
|
Trafford
|
275.4
|
|
Manchester
|
736.0
|
|
Oldham
|
304.1
|
|
Tameside and Glossop
|
308.6
|
|
Stockport
|
349.9
|
|
North Yorkshire and York
|
870.0
|
|
East Riding of Yorkshire
|
345.7
|
|
Hull Teaching
|
371.3
|
|
North Lincolnshire
|
190.4
|
|
North East Lincolnshire
|
210.4
|
|
Rotherham
|
330.2
|
|
Doncaster
|
401.6
|
|
Sheffield
|
721.8
|
|
Barnsley
|
319.9
|
|
Wakefield
|
444.5
|
|
Kirklees
|
485.1
|
|
Calderdale
|
254.6
|
|
Bradford and Airedale Teaching
|
655.5
|
|
Leeds
|
952.0
|
|
County Durham
|
711.8
|
|
Northumberland Care Trust
|
399.1
|
|
Sunderland Teaching
|
413.3
|
|
Newcastle
|
386.4
|
|
North Tyneside
|
273.2
|
|
Gateshead
|
286.7
|
|
North Tees
|
228.1
|
|
South Tyneside
|
223.0
|
|
Middlesbrough
|
208.8
|
|
Redcar and Cleveland
|
189.4
|
|
Darlington
|
136.4
|
|
Hartlepool
|
131.9
|
